Back to top
more

Regeneron Pharmaceuticals (REGN)

(Real Time Quote from BATS)

$829.72 USD

829.72
529,641

+13.07 (1.60%)

Updated Nov 7, 2024 03:02 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth D Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (89 out of 251)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Sanofi's (SNY) Dupixent Gets Europe Nod for Prurigo Nodularis

by Zacks Equity Research

The EC approves Sanofi (SNY) and its partner Regeneron's Dupixent for the treatment of adult patients with prurigo nodularis.

Regeneron (REGN) Presents Positive Data on MM and FL Drugs

by Zacks Equity Research

Regeneron (REGN) releases positive initial data on two candidates - linvoseltamab and odronextamab at ASH.

Regeneron's (REGN) sBLA for Evkeeza Gets FDA Priority Review

by Zacks Equity Research

The FDA accepts for priority review Regeneron's (REGN) sBLA for Evkeeza for treating children aged five to 11 years with homozygous familial hypercholesterolemia. A decision is due on Mar 30, 2023.

Should Goldman Sachs Equal Weight U.S. Large Cap Equity ETF (GSEW) Be on Your Investing Radar?

by Zacks Equity Research

Style Box ETF report for GSEW

Regeneron (REGN) Outperforms YTD: What's in Store for 2023?

by Zacks Equity Research

Regeneron (REGN) has had a good run in 2022 so far and the momentum should continue in 2023 as well.

Biotech Stock Roundup: CTMX Surges on REGN's Deal, APLS Up on Regulatory Update

by Zacks Equity Research

Updates from CTMX and APLS are the key highlights from the biotech sector during the past week.

Regeneron's (REGN) Libtayo Gets EC Nod for Cervical Cancer

by Zacks Equity Research

Regeneron (REGN) gets EC's approval for the label expansion of PD-1 inhibitor Libtayo for the treatment of adult patients with recurrent or metastatic cervical cancer.

CytomX (CTMX) Stock Surges on Oncology Deal With Regeneron

by Zacks Equity Research

CytomX (CTMX) gets a boost after its deal with Regeneron for the development of investigational next-generation bispecific immunotherapies.

Bayer (BAYRY) Eylea Label Extension Gets CHMP Positive Opinion

by Zacks Equity Research

Bayer (BAYRY) gets positive recommendation from the CHMP for label extension of ophthalmology drug Eylea for the treatment of preterm infants with retinopathy of prematurity.

Sanofi (SNY), Regeneron Dupixent Gets CHMP Nod for Skin Disease

by Zacks Equity Research

The CHMP recommends approval of Sanofi's (SNY) Dupixent for the treatment of prurigo nodularis, a chronic inflammatory skin disease.

Kodiak Sciences' (KOD) Q3 Earnings Beat, Eye Candidate in Focus

by Zacks Equity Research

Kodiak Sciences (KOD) reports a narrower-than-expected loss for the third quarter of 2022. The focus is on the lead candidate, KSI-301, developed for treating various retinal vascular diseases.

Biotech Stock Roundup: REGN, AMGN, MRNA's Q3 Earnings, VERV Down on Update

by Zacks Equity Research

Earnings updates from REGN and MRNA are the key highlights from the biotech sector during the past week.

Regeneron (REGN) Gets FDA Nod for Libtayo's Label Expansion

by Zacks Equity Research

Regeneron (REGN) obtains FDA approval for the second advanced NSCLC indication, which expands the patient population eligible for a Libtayo-based regimen to include combination treatment with chemotherapy, irrespective of PD-L1 expression levels.

Bayer's (BAYRY) Q3 Earnings Miss Estimates, Revenues Top

by Zacks Equity Research

Bayer's (BAYRY) earnings fall shy of estimates in the third quarter of 2022 while revenues beat the same.

Intellia's (NTLA) Q3 Loss Wider Than Expected, Revenues Up Y/Y

by Zacks Equity Research

Intellia Therapeutics (NTLA) posts a wider-than-expected Q3 loss and sales also miss the mark. NTLA continues to advance its pipeline with developmental programs.

Regeneron (REGN) Q3 Earnings & Sales Beat on Eylea, Dupixent

by Zacks Equity Research

Regeneron (REGN) tops earnings and sales estimates for the third quarter, driven by its lead drug Eylea and profits from the asthma drug, Dupixent. However, earnings decline year over year.

Regeneron (REGN) Surpasses Q3 Earnings and Revenue Estimates

by Zacks Equity Research

Regeneron (REGN) delivered earnings and revenue surprises of 14.85% and 5.08%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Kinjel Shah headshot

Drug, Biotech Stocks' Q3 Earnings on Nov 3: AMGN, REGN & More

by Kinjel Shah

Let us look at five drug and biotech companies, AMGN, REGN, ZTS, and MRNA, which are gearing up for their earnings release.

UniQure (QURE) Reports Q3 Loss, Misses Revenue Estimates

by Zacks Equity Research

uniQure (QURE) delivered earnings and revenue surprises of 8.11% and 86.46%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Sheraz Mian headshot

Top Stock Reports for Exxon Mobil, T-Mobile US & Intuitive Surgical

by Sheraz Mian

Today's Research Daily features new research reports on 16 major stocks, including Exxon Mobil Corporation (XOM), T-Mobile US, Inc. (TMUS) and Intuitive Surgical, Inc. (ISRG).

Regeneron (REGN) Q3 Earnings Coming Up: What's in the Cards?

by Zacks Equity Research

Regeneron's (REGN) third-quarter earnings are likely to have got a boost from the solid performance of Eylea and Dupixent.

Should Invesco S&P 500 GARP ETF (SPGP) Be on Your Investing Radar?

by Zacks Equity Research

Style Box ETF report for SPGP

Sanofi (SNY) Q3 Earnings Beat, Dupixent, Flu Jabs Push Sales

by Zacks Equity Research

Sanofi (SNY) beats third-quarter estimates for earnings and sales. Dupixent and flu vaccines drive sales growth. The company raises its earnings growth guidance for 2022.

Why Regeneron (REGN) Could Beat Earnings Estimates Again

by Zacks Equity Research

Regeneron (REGN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Alnylam's (ALNY) Earnings and Revenues Lag Estimates in Q3

by Zacks Equity Research

Alnylam's (ALNY) earnings and sales fall shy of estimates in the third quarter of 2022. The company maintains its product revenue guidance for 2022.